Stem cell gene transfer treats IL-1 immune diseases
Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.
Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.
An anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway.
A new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology.
Carbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions.
Roche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
Belgian T reg specialist Dualyx NV had raised 40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
French pancreatic beta-cell modulator specialist DiogenX SA has raised 27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for 100m.